Inhibrx is a clinical-stage biotechnology company with a pipeline of biologic therapeutic candidates, developed using its protein engineering expertise and proprietary single domain antibody, or sdAb, platform. Co.'s sdAb platform allows it to pursue validated targets with clinical promise, but where other antibody and biologic based approaches have failed. Co.'s existing pipeline is focused on oncology and orphan diseases. Co. has four programs in ongoing clinical trials. Three of these programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency. Co.'s pipelines include: INBRX-10, INBRX-109, INBRX-106, and INBRX-105. The INBX stock yearly return is shown above.
The yearly return on the INBX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the INBX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|